Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

Sativex study boosts GW Pharma

Shares in GW Pharmaceuticals received a much needed boost this morning after the Journal of Clinical Therapeutics published the results of a study which showed that Sativex(R) provided "effective long term treatment of neuropathic pain in Multiple Scherosis (MS)". The study also said that benefits of Sativex were obtained "without any evidence of tolerance to the medicine"....
no_picture_pai.jpg
Shares in GW Pharmaceuticals received a much needed boost this morning after the Journal of Clinical Therapeutics published the results of a study which showed that Sativex(R) provided "effective long term treatment of neuropathic pain in Multiple Scherosis (MS)". The study also said that benefits of Sativex were obtained "without any evidence of tolerance to the medicine".

The results of the study are a boost for GW Pharma, which despite gaining approval for the use of Sativex(R) in Canada, is still attempting to gain access to the U.S. Market. The company said that a "pivotal" Phase III trail into MS neuropathic pain had recruited 339 patients. and would the be largest clinical trial to date. Results from the Phase III trial are expected in the first half of 2008.

Salvitex(R) is produced from two key ingredients derived from the cannabis plant.

Dr Stephen Wright, GW Pharma's R&D Director added "The results add to what we know from short-term clinical trials, and we look forward to seeing the results of our ongoing pivotal study in the same condition in the first half of next year."
View full GWP profile View Profile

GW Pharmaceuticals Timeline

Related Articles

nizoral shampoo
June 19 2018
The new product will be the company's fourth international star brand
scientist in lab
September 11 2018
The phase 1b trial of Silence’s lead candidate, SLN124, a treatment for a rare blood disorder, is scheduled to begin in the second half of 2019
Once the phase III trial is completed, Futura plans to either sell off the asset or find a partner
September 26 2018
The pharma group expects to dose the first patient in the Phase III trial of its MED2002 erectile dysfunction treatment within the next month

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use